Lactoferrin Bovine
ApprovedSmall molecule
Lactoferrin Bovine is one of 73 small molecule programs targeting Iron deficiency anemia. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
135 competitors in Encephalopathy
#DrugCompanyPhaseTrials
1Xifaxan
SSalix
Phase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Alinia
RRomark Laboratories L.C.
Phase 3
PROCRIT
WWim Janssens
Phase 3
Cafcit
KKaken Pharmaceutical
Phase 3
VSL#3
CCD Pharma India Pvt. Ltd.
Phase 3
Erythropoietin-Beta
RochePhase 3
Citicoline
UUniversity of Texas Southwestern Medical Center
Phase 3
Magnesium SO4
HHospital de Base
Phase 3
Lactoferrin Bovine
AAl-Azhar University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Encephalopathy1 trial
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
Unknown status·—·Phase 2·NCT06072521·45 enrolled
Invasive Fungal Infections1 trial
Effect of Administration of Combined Enteral Lactoferrin and Probiotic On Invasive Fungal Infections In Preterm Neonates
Completed·—·Phase 1·NCT05283278·80 enrolled
Iron deficiency anemia1 trial
Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia
Completed·—·Phase 4·NCT04267653·96 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lactoferrin Bovine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAl-Azhar University